Reported results
- Generated total revenues of $794.0 million in the third quarter of 2026, representing a GAAP increase of 34.1% compared to the third quarter of 2025.
- Generated a gross margin of 64.7% in the third quarter of 2026, compared to 64.9% in the third quarter of 2025.
- Processed approximately 1,093,100 tests in the third quarter of 2026, compared to approximately 893,600 tests in the third quarter of 2025.
- Net loss for the third quarter of 2026 was $59.9 million, or ($0.42) per diluted share, compared to a net loss of $87.5 million, or ($0.64) per diluted share, in the third quarter of 2025.
- Held approximately $1,097.2 million in cash, cash equivalents, and restricted cash as of September 30, 2026.
Guidance
- Anticipates 2026 total revenue of $3.005 billion to $3.035 billion.
- Anticipates gross margin to be approximately 64% to 66%.
- Anticipates selling, general and administrative costs to be approximately $1.225 billion to $1.300 billion.
- Anticipates research and development costs to be $825 million to $925 million.
- Anticipates cash flow to be positive.
Price and volatility reaction
The stock moved -14.6% on the print. No front-expiry chain was on file, so there is no straddle expected move. 30-day ATM implied volatility moved -10.0 vol points across the event (constant-maturity series — not the front-week crush).
| Measure | Value | Basis |
|---|---|---|
| Close before release | 363.76 | 2026-11-05 |
| Close after release | 310.67 | 2026-11-06 |
| Realised move | -14.6% | close to close |
| 30d ATM IV change | -10.0 vol pts | constant-maturity series, not the front expiry |
Source
The figures above come from the earnings release the company filed with the SEC on 2026-11-05 (8-K, Item 2.02). Read the original filing on sec.gov.
